Posted by Michael Wonder on 29 Sep 2022
Fore Biotherapeutics announces fast track designation granted by FDA to FORE8394 for the treatment of cancers harbouring BRAF class 1 and class 2 alterations
28 September 2022 - FORE8934 currently being evaluated in Phase 1/2a trial for the treatment of advanced solid and CNS tumours with BRAF alterations.
Fore Biotherapeutics today announced that the U.S. FDA has granted fast track designation to FORE8934, its investigational, novel, small-molecule, orally available inhibitor for the treatment of patients with cancers harbouring BRAF Class 1 (V600) and Class 2 (including fusions) alterations who have exhausted prior therapies.
